Home/Filings/4/0001209191-17-031374
4//SEC Filing

Ovid Therapeutics Inc. 4

Accession 0001209191-17-031374

$OVIDCIK 0001636651operating

Filed

May 9, 8:00 PM ET

Accepted

May 10, 5:14 PM ET

Size

9.8 KB

Accession

0001209191-17-031374

Insider Transaction Report

Form 4
Period: 2017-05-10
During Matthew
DirectorPresident and CSO10% Owner
Transactions
  • Conversion

    Series A Preferred Stock

    2017-05-1028,2450 total
    Common Stock (28,245 underlying)
  • Conversion

    Common Stock

    2017-05-10+28,2454,307,314 total
Holdings
  • Common Stock

    (indirect: By Trust)
    93,023
  • Common Stock

    (indirect: By Trust)
    93,023
  • Common Stock

    (indirect: By Trust)
    93,023
  • Common Stock

    (indirect: By Trust)
    93,023
Footnotes (1)
  • [F1]The Series A Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date.

Issuer

Ovid Therapeutics Inc.

CIK 0001636651

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001636651

Filing Metadata

Form type
4
Filed
May 9, 8:00 PM ET
Accepted
May 10, 5:14 PM ET
Size
9.8 KB